Myra Vision

What an exciting weekend at the International Glaucoma Consortium (IGC) 2024 in Salt Lake! Thank you to Dr. Peter Chang from Baylor College of Medicine for highlighting Myra Vision's "readiness" during the "Alternative Bleb Procedures: Ready or Not?" and to Dr. Austin Nakatsuka from the Moran Eye Center University of Utah for showcasing our "Titratable Device" with an update on the Calibreye Titratable Glaucoma Therapy™ Surgical System. Exciting times ahead as Myra continues toward its goal of changing the standard of #glaucoma care. #innovation #startup #makingadifference #IOP

Fantastic time seeing the latest in ophthalmology #innovation firsthand and connecting with industry leaders at last week's American Academy of Ophthalmology's Annual meeting (#AAO2024) in Chicago. We also enjoyed showcasing Myra's Calibreye Titratable Glaucoma Therapy™ Surgical System during the Innovators Pop Up. Calibreye aims to change the standard of #glaucoma care with its adjustable outflow control technology and offers the potential to provide personalized #IOP control so physicians are able to address the evolving needs of their patients. #startup #makingadifference

CEO Robert Chang shares his insights on how Myra Vision's Calibreye Titratable Glaucoma Therapy™ Surgical System aims to change the standard of #glaucoma care with its adjustable outflow control technology. This #innovation has the potential to provide personalized #IOP control so physicians can address the evolving needs of their patients. You won't want to miss this interview during the Innovators Pop Up in Chicago, October 17th. #startup #makingadifference

Myra Vision is focused on bringing #innovation to #glaucoma care. Thank you to Glaucoma Physician and Dr. Shivani Kamat for highlighting our Calibreye Titratable Glaucoma Therapy™ Surgical System as one of the next-generation drainage implants that may offer effective ways to lower #IOP with potentially improved safety profiles. Check out the full article here: https://lnkd.in/evfJ55xm

Great energy and enthusiasm at #OFF2024 for Robert Chang's update presentation on Myra Vision's Calibreye Titratable Glaucoma Therapy™ Surgical System.   Thank you to all those that organized and attended last week's session!  #glaucoma #IOP #innovation #startup #makingadifference

Myra Vision’s Calibreye Titratable Glaucoma Therapy™ Surgical System aims to advance the future of #glaucoma care through innovative adjustable outflow control. Don’t miss Myra's CEO, Robert Chang, present the latest on the company's progress on Thursday, September 5th at the 2024 Ophthalmology Futures Forum in Barcelona. #IOP #innovation #startup #makingadifference

Check out this Glaucoma Today article and see what Dr. Arsham Sheybani thinks of modulating aqueous flow with the Calibreye™ Titratable Glaucoma Therapy™ Surgical System.   https://lnkd.in/ef6bxKBx #glaucoma #IOP #innovation #startup #makingadifference

Exciting few days in Dublin for Myra Vision! Many thanks to Dr. Sheybani Arsham for highlighting the company's #Calibreye during the Titratable Devices portion of the Rapid-Fire New Technology session at the Interventional #Glaucoma Consortium (IGC) 2024 last week and then again with a poster at the European Glaucoma Society (EGS) 2024 over the weekend.  #innovation #startup #makingadifference #IOP

Thank you to Ophthalmology Times for the great coverage of Myra Vision's presentation at this week's Association for Research in Vision and Ophthalmology (ARVO) meeting!  https://lnkd.in/eNhdMuRk #glaucoma #IOP #innovation #ARVO2024 #startup #makingadifference

Myra Vision was prominently showcased during the Association for Research in Vision and Ophthalmology (ARVO) “Vision for the Future” #ARVO2024 meeting this week in Seattle! We are thankful for Dr. Ariana Levin from NYU who presented details of Myra’s Calibreye™ Titratable Glaucoma Therapy™ (TGT) System, a novel #glaucoma shunt that allows for titratable flow post-implantation and Dr. Austin Nakatsuka from the University of Utah Health for his poster summarizing a histopathological evaluation of the Myra’s innovative technology compared to a commercially available aqueous shunt. Thank you both for your partnership and support as we look to bring #innovation to #glaucoma care and preserve vision for patients with moderate to severe glaucoma. CAUTION: Investigational device. Myra Vision’s Calibreye™ Titratable Glaucoma Therapy™ (TGT) System is for investigational use only and not yet available for sale. #startup #makingadifference